FDA's TEMPO Pilot Speeds Up Safe Digital Health Device Access
Published Date: 12/8/2025
Notice
Summary
The FDA is launching the TEMPO pilot to help get cool digital health devices to patients faster while keeping safety a top priority. Starting January 2, 2026, device makers can apply to join this program, which ties payments to real health improvements for people with chronic diseases. This means better care, new tech, and smarter spending for patients and providers alike!
Analyzed Economic Effects
5 provisions identified: 3 benefits, 1 costs, 1 mixed.
Possible Enforcement Discretion for Participants
Manufacturers may ask FDA to exercise enforcement discretion so FDA will not enforce certain legal requirements when their device is offered to or by CMMI ACCESS participants for an intended use to improve patient outcomes. FDA lists examples such as premarket authorization requirements, investigational device exemption (IDE) requirements, and requirements under 21 CFR parts 50 and 56.
Required Real-World Data Collection and Reporting
Manufacturers participating in the TEMPO pilot are expected to collect real-world data (RWD) about their device's intended use, share those data with FDA during participation, and use the data to seek marketing authorization. FDA also requests proposed interim reporting (for example, every 6 months) to report adverse events, new risks, and progress.
Limited US-Based Participant Slots
FDA currently expects to select up to about ten manufacturers based in the United States in each of four clinical use areas for the TEMPO pilot. FDA intends to select U.S.-based manufacturers to facilitate oversight such as inspections and access to records.
Pilot Focus on Four Clinical Use Areas
FDA will consider devices intended for clinician-supervised outpatient treatment in these four clinical use areas: (1) early cardio-kidney-metabolic (hypertension, dyslipidemia, obesity or overweight with marker of central obesity, or prediabetes); (2) cardio-kidney-metabolic (diabetes, chronic kidney disease, or atherosclerotic cardiovascular disease); (3) musculoskeletal (chronic musculoskeletal pain); and (4) behavioral health (depression or anxiety).
Applications Open January 2, 2026
If you make digital health devices, you can submit a "Statement of Interest for Participation in the TEMPO Pilot" starting January 2, 2026. FDA says it will begin follow-up requests to potential participants around March 2, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-22188, Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. They’re asking for comments by February 6, 2026, to make sure the process is clear, useful, and not too much work. This affects anyone who might provide info to CMS and helps keep things running smoothly without wasting time or money.
Next: 2025-22191, Agency Information Collection Activities: Requests for Comments; Clearance of Renewed Approval of Information Collection: FAA Advisory Circular 120-119, Voluntary Safety Management System for Other Regulated Entities Transporting Dangerous Goods by Air
The FAA is renewing approval for a voluntary safety program that helps companies safely transport dangerous goods by air. This affects businesses that choose to follow FAA safety guidelines and submit their safety plans for review. Comments on this renewal are open until January 7, 2026, with no new fees or major changes involved.